Key Milestones in Clinical Trial History

The British historian Arnold Toynbee believed that civilizations evolve through an ongoing process of challenge and response. Each society will face challenges. Their systems and institutions advance or weaken based on the ability to provide an adequate response.

If a challenge is too weak, it does not encourage society to grow or innovate. If a challenge is too severe, it causes utter collapse. The best type of challenge is somewhere in the “Goldilocks” zone. It instills urgency without overwhelming. These crises pose a powerful threat, perhaps existential, that prompts societies to lead with bold and creative solutions.

The global clinical research ecosystem is a foundation of our civilizational infrastructure. This year, in commemoration of Clinical Trials Day, the Landrich Group explores key milestones in its evolution. Each was an institutional response to a prior failure that addressed gaps in the previous framework.

1. The Scurvy Trial (1747)

James Lind was a Scottish naval surgeon who divided 12 patients with scurvy into 6 pairs and assigned each pair a different treatment. One pair was given oranges and lemons. They were the only ones who recovered. Through this experiment, Lind executed one of the first and most widely known controlled comparisons, identifying a single variable and holding everything else constant to observe the results. In doing so, Lind and other pioneers overturned two thousand years of assumptions about medical practice.

2. Statistics and the Streptomycin RCT (1920s-1940s)

In the 1920s, a British agricultural researcher named Ronald Fisher created a mathematical framework for experimental design. This included the concepts of randomization, analysis of variance, and the p-value. This helped minimize selection bias and provided a method for statistical inference to define uncertainty. When this framework was applied to medicine, the 1948 streptomycin trial for tuberculosis marked the formal birth of the modern RCT (randomized controlled trial).

3. The Thalidomide Scandal (1957-1962)

This was a sedative initially developed and marketed in Europe for morning sickness in pregnant women. After its public distribution in 1957, it is estimated to have caused 10,000 birth defects. The tragedy revealed that the pre-war regulatory framework, which relied primarily on pharmaceutical companies to regulate, was no longer acceptable in the era of synthetic chemistry and mass-market pharmaceutical production. The 1962 Kefauver-Harris Amendment transformed the FDA into an agency that required proof of both safety and efficacy. Other governments followed suit, creating the regulatory apparatus that governs clinical trials today.

4. The Declaration of Helsinki, Tuskegee, and the Belmont Report (1964-1979)

After World War II, the Nuremberg Code established informed consent as a response to the Nazi medical experiments. The Helsinki principles, adopted by the World Medical Association, extended these principles to mainstream clinical research. Despite these milestones, scandals like the Tuskegee syphilis study exposed ongoing failures in the ethical treatment of participants. In reaction to the Tuskegee scandal, the 1979 Belmont Report specified an ethical framework for U.S. regulations and the Institutional Review Board system, making independent ethics review mandatory.

5. The HIV/AIDS Epidemic and Patient Activism (late-1980s)

In the late 1980s, AIDS had killed over 40,000 Americans. Patient activist groups like ACT UP (The AIDS Coalition to Unleash Power) developed one of the most sophisticated advocacy campaigns in history. They challenged the FDA to accelerate the standard 10-year drug approval timeline and change key aspects of trial design. They advocated for the position that patients had a right to parallel access to experimental drugs while trials were ongoing. They also argued that placebo-controlled trials for a fatal disease were deeply unethical. The FDA responded with major reforms to accelerate approvals and allow broader access to drugs during trials based on patient activist demands.

6. ICH and the Globalization of Trial Infrastructure (1990)

In 1990, the International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use created a unified framework for trials for the US, EU, and Japan. This standardization enabled clinical research at a global scale, enabling multinational trials that could be scaled geographically to lower-cost environments such as China, India, Latin America, and Eastern Europe. Under the harmonized framework, Asia has experienced a surge in clinical research activity.

7. Trial Registration, Transparency and the p-Value Reckoning (1996-2005[DP1] )

John Ioannidis’s 2005 paper “Why Most Published Research Findings Are False” was a major critique of clinical trial methodology. Analysis showed that the p < .05 threshold, long considered a statistically significant gold standard, had been manipulated in multiple studies (this became known as “p-hacking”. This accelerated the adoption of transparency reforms already underway. The CONSORT statement in 1996 had defined specific standards for reporting on key trial elements like flow diagrams, pre-specified outcomes, and endpoints. Registration on ClinicalTrials.gov, launched in 2000, became a de facto requirement for publication in major journals. Once again, a challenge from within the field mobilized the broader community to reform.

8. The Genomic Revolution (2000-2015)

The completion of the Human Genome Project in the early 2000s occurred in parallel with the approval of the first targeted cancer therapies. Imatinib (Gleevec) was approved for BCR-ABL-positive chronic myeloid leukemia and trastuzumab (Herceptin) for HER2-positive breast cancer. The success of these targeted therapies created a new approach to trial design. A target population of patients could be defined by a molecular subgroup, instead of a broad disease category. In the 2010s, the FDA provided further guidance on adaptive trial designs and breakthrough therapy guidance. This enabled a new drug-diagnostic model, allowing smaller, targeted trials enrolling patients selected by biomarkers.

9. COVID-19 and the Speed Proof-of-Concept (2020)

The SARS-CoV-2 pandemic produced the fastest vaccine development in history. The pandemic tested assumptions about why clinical trials take as long as they do. Regulatory review, manufacturing scale-up, site activation, patient recruitment, IRB review, and data management were dramatically compressed. The Pfizer-BioNTech and Moderna mRNA vaccines went from sequence to Emergency Use Authorization (EUA) in under a year. SOLIDARITY, the WHO's global platform trial, tested multiple therapeutics simultaneously across dozens of countries with unprecedented coordination. The infrastructure built during COVID, from platform trial networks to regulatory precedents, created a foundation for mRNA application to cancer, influenza, and HIV during the next decade. The COVID pandemic also accelerated the implementation of risk-based monitoring, a concept introduced by the FDA and other regulators in 2013[DP2] .

10. Our Current Inflection Point (Present)

Technological advances are once again creating pressure on the current framework:

• Real-world evidence is now accepted by regulators for label expansions and approvals, but the evidence standards remain contested.

• Artificial Intelligence (AI) in trial design is widely adopted for operational tasks like patient recruitment, safety monitoring, and site selection. However, its use in primary evidence generation – such as the use of digital twins and synthetic control arms – is largely undefined in terms of regulatory acceptance.

• Decentralized trials have accelerated since COVID, eliminating geographic access limitations. However, this risk creates new barriers based on digital technology access.

Conclusion

Globalization, information technology, and life science innovation have dramatically transformed clinical research in the 21st century. One through line since James Lind’s scurvy trial is the premise that prospective, controlled, randomized human trials are required for the approval of a new therapy. A study identifies a finite number of human participants, follows them forward in time, collects their data, and then makes a final assessment on safety and efficacy. Will that foundation hold for the next 25 years? Or will it expand to accommodate AI-powered evidence and real-time systems available through new technologies? Join us in part 2 of this series, where we explore the key factors defining the future of clinical trials.

Exploring the trends that will influence your clinical research strategy?  Let's discuss. Landrich Group combines deep expertise and a forward-looking approach to support our clients and partners!